Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
Open Access
- 1 May 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 126 (5) , 1127-1135
- https://doi.org/10.1093/brain/awg119
Abstract
We have studied the progression of striatal and extrastriatal post‐synaptic dopaminergic changes in a group of 12 patients with Huntington’s disease using serial 11C‐raclopride PET, a specific marker of D2 dopamine receptor binding. All patients had two 11C‐raclopride PET scans 29.2 ± 12.8 months apart, and six of them had a third scan 13.2 ± 3.9 months later. We found a mean annual 4.8% loss of striatal 11C‐raclopride binding potential (BP) between the first and second scans, and a 5.2% loss between the second and third scans. Statistical Parametric Mapping (SPM) localized significant baseline reductions in 11C‐raclopride BP in both striatal and extrastriatal areas, including amygdala, temporal and frontal cortex in Huntington’s disease compared with normal subjects matched for age and sex. When the 11C‐raclopride scans performed 29 months after the baseline scans were considered, SPM revealed further significant striatal, frontal and temporal reductions in 11C‐raclopride BP in Huntington’s disease. Cross‐sectional Unified Huntington’s Disease Rating Scale (UHDRS) scores correlated with 11C‐raclopride binding, but there was no correlation between individual changes in UHDRS motor scores and changes in striatal binding. Performance on all neuropsychological measures deteriorated with time but only the accuracy score of the one‐touch Tower of London test correlated significantly with striatal and putamen D2 binding. In summary, serial 11C‐raclopride PET demonstrates a linear progression of striatal loss of D2 receptors in early clinically affected Huntington’s disease patients over 3 years. SPM also revealed a progressive loss of temporal and frontal D2 binding. Changes over time in clinical scores and in neuropsychological assessments, except for measures of planning, did not correlate with striatal D2 binding. This probably reflects both contributions from other affected brain structures and high variance in these measures.Keywords
This publication has 32 references indexed in Scilit:
- Retest effects and cognitive decline in longitudinal follow-up of patients with early HDNeurology, 2001
- The amygdala: vigilance and emotionMolecular Psychiatry, 2000
- Motor and cognitive improvements in patients with Huntington's disease after neural transplantationThe Lancet, 2000
- Huntington's disease progressionBrain, 1999
- [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat lengthAnnals of Neurology, 1998
- Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumesBrain, 1997
- Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's diseaseBrain, 1996
- Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.Proceedings of the National Academy of Sciences, 1996
- Functional repair of striatal systems by neural transplants: evidence for circuit reconstructionBehavioural Brain Research, 1995
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989